Point to consider 5: Summary of included studies describing the prognostic value of the imaging modalities
| Reference | No. of subjects | Duration of follow-up (months) | Radiological or clinical assessment | Outcome assessed | Correlation | |
|---|---|---|---|---|---|---|
| Baseline CR predictive factors | ||||||
| Susic et al120 | 87 | 48 | Wrist involvement | CHAQ-DI | Significant correlation p<0.01 | |
| Hip involvement | Significant correlation p<0.001 | |||||
| JADI-A | Significant correlation p<0.01 | |||||
| Ravelli et al29 | 96 | min. 60 | CR wrist changes at: baseline in 1st year in 1st 5 years | No. of joints with LOM | Baseline: low r=0.16 1st year: low r=0.35 1st 5 years: moderate r=0.59 | |
| JADI-A | Baseline: low r=0.21 1st year: moderate r=0.53 1st 5 years: moderate r=0.60 | |||||
| Steinbocker functional class | Baseline: low r=0.21 1st year: moderate r=0.48 1st 5 years: moderate r=0.55 | |||||
| CR progression at 5 years | Baseline: low r=0.38 1st year: moderate r=0.61 1st 5 years: high r=0.89 | |||||
| Pederzoli et al30 | 130 | min. 60 | CR wrist a SH score > 1 | CR progression at 5 years | Significant predictor OR 8.2 | |
| Magni-Manzoni et al28 | 94 | 54 | Baseline Poznanski score | CR progression in 1st yr | ||
| Baseline Poznanski score | Yearly CR progression | r=0.88 p=0.47 | r=0.62, p<0.001 OR 14.32, p<0.0001 | |||
| CR wrist progression in 1st year | Final Poznanski score | r=0.58 p<0.0001 | r=0.59, p<0.0001 OR 6.49, p=0.0006 | |||
| CHAQ | r=0.20 p=0.14 | r=0.39, p=0.003 OR 8.42, p=0.002 | ||||
| Bertamino et al27 | 148 | max. 132 | CR hip progression in 1st year | CHAQ | r=0.24, p=0.1 | |
| SJC | r=0.03, p=0.86 | |||||
| TJC | r=0.06, p=0.65 | |||||
| No. of joints with LOM | r=0.46, p=0.0005 | |||||
| Steinbocker functional class | r=0.50, p=0.005 | |||||
| JADI-A | r=0.45, p=0.01 | |||||
| Physician disability score | r=0.40, p=0.05 | |||||
| Parent disability score | r=0.53, p=0.007 | |||||
| Oen et al121 | 136 | min. 60 | Early (<2 years) erosions/JSN | CHAQ | No correlation | |
| Selvaag et al122 | 197 | 36 | Baseline swelling/osteopenia | CR erosive progression | OR 7.95, p<0.001 | |
| Less patients with CR progression had CHAQ of 0, p=0.045 | ||||||
| Ringold et al31 | 104 | 29.9 | Early (<6 months) erosions/JSN vs normal | Time with active disease CRM | More time with active disease p<0.001 Less chance of CRM, RR=0.34, p<0.001 | |
| RF +ve vs −ve | More time with active disease p=0.07 | |||||
| Oen et al54 | 88 | Early (<2 years) Late (1–20.8 years) | Late vs early JSN | CHAQ | Significant correlation Explains 17.7% of variation in CHAQ | |
| Joint pain | Explains 32.4% of variation in CHAQ | |||||
| Habib et al123 | 68 | – | ACPA | CR erosions | Significant correlation p=0.004 | |
| Arvidsson et al124 | 103 | 324 | Baseline/early TMJ involvement | Micrognathia | 66.7% patients with micrognathia had baseline TMJ involvement; 33.3% had CR TMJ involvement within 2 years | |
| Baseline MRI predictive factors | ||||||
| Malattia et al32 | 58 | 12 | Baseline wrist synovial volume | MRI erosive progression | Correlation r=0.42 p<0.02 All patients with high synovial volume had erosive progression | |
| Baseline CRP | Correlation r=0.40 p<0.02 | |||||
| Gardner-Medwin et al125 | 10 | 12 | Baseline synovial hypertrophy in a clinically normal joint | Disease extension from monoarthritis | 100% patients developed clinical arthritis in other joints | |
ACPA, anticyclic citrullinated peptide antibody; aSH, adapted Sharp van der Heijde score; CHAQ-DI, Childhood Health Assessment Questionnaire disability index; CR, conventional radiography; CRM, clinical remission on medication; CRP, C reactive protein; JADI-A, Juvenile Arthritis Damage Index for articular damage; JSN, joint space narrowing; LOM, limitation of movement; RF, rheumatoid factor; +ve, positive; −ve, negative; RR, relative risk; SJC, swollen joint count; TJC, tender joint count; TMJ, temporomandibular joint.